Abstract: Among adult participants, factors associated with preexisting M184 V/I included other resistance, Black race, Hispanic/Latinx ethnicity, lower baseline CD4 cell count, advanced HIV disease, longer duration of antiretroviral therapy, and greater number of prior third agents.
Abstract: At last on-treatment visit, 98% (179/182) with preexisting M184 V/I and 99% (2012/2034) of all B/F/TAF-treated participants had HIV-1 RNA <50 copies/mL, with no treatment-emergent resistance to B/F/TAF.
Abstract: CONCLUSIONS: M184 V/I was detected in 10% of virologically suppressed clinical trial participants at study baseline.
Abstract: Most substitutions were M184 V (n = 161) or M184 V/I mixtures (n = 10).
Abstract: OBJECTIVE: We in
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Discussion: A combination of RAM similar to those found in this case (M184V, K65R, V108I and E138A) has not been reported in PrEP users.
Discussion: Although theoretically possible, it is unlikely that the short-term and limited drug exposure was sufficient to select for both M184V and K65R, with only few M184V mutations, and even more rarely K65R, described in the literature.
Discussion: However, six cases of HIV infection despite PrEP use have been described previously; in two cases both M184V and K65R were identified.
Discussion: Possible explanations for the PrEP failure in our
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Discussion: In the other trial, STAT, dolutegravir plus lamivudine (DOVATO (c)) were administered in STR to 131 patients; this regimen was modified in 8 patients during the first 24 weeks (5 for HBV infection, 1 for M184V mutation in baseline GRT, 1 for adverse effects, and 1 by patient request).
Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure.
PMID: 35302390
2022
AIDS research and human retroviruses
Abstract: M184V/I, K103N/S and Y181C were the most commonly occurring mutations, seen in 76%, 51% and 36% children.
Abstract: At BL, K103N (5), E138A/G (4) and M184V (3) were the most common mutations.
Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Result: M184V (0.23%, 2/865) was the most common nucleoside reverse transcriptase inhibitors (NRTIs) related mutation followed by T69D (0.12%, 1/865) and T69G (0.12%, 1/865).
Result: NGS was more sensitive in detecting low-frequency mutations and a total of 4 mutations were detected by NGS but missed by Sanger sequencing which including M184V (1.31%), K65E (3.72%), E138G (1.21%), and Y188C (1.04%).
Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report.
PMID: 35164871
2022
Journal of medical case reports
Conclusion: At the point of CSF escape diagnosis, the CD4 cell count was 180 cells/mm3, and both plasma and CSF harbored the same NRTI M184V mutation.
Conclusion: The NRTI M18
Conclusion: The HIV-1 pol gene genotypic resistance analysis showed development of the NRTI M184V mutation, and NNRTI K103N and E138EK mutations in plasma, respectively.
Discussion: Cerebrospinal fluid escape is seen after more than 15 years of HIV infection, previous low-level viremia, and the presence of M184V/I mutations in the CSF.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
PMID: 34694877
2022
Antimicrobial agents and chemotherapy
Result: One participant (participant 1) had the integrase substitution R263R/K and NRTI resistance-associated substitutions K65R and M184I/V at baseline, despite no apparent prior INSTI treatment, but did not demonstrate in vitro dolutegravir phenotypic resistance.
Result: The
Discussion: Six participants received zidovudine as the active background agent, and all had M184V resistance substitutions with prior lamivudine or emtricitabine treatment.
Discussion: Unusually, 1 participant had the highly conserved integrase substitutions R263R/K and M184I/V as mixtures at baseline but not at CVW.
High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
Abstract: The predominant DRMs for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs).
HIV mutation literature information.
PMID: 
2022
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT